Hong Kong’s OrbusNeich raises $200m

Additional investors include CCB International, CICC Biomedical Fund, China Merchants Securities, and Shenzhen Share Capital Healthcare Fund. The proceeds will support R&D and accelerate growth in new product areas, both in Greater China and overseas, according to a statement.

Founded in 2000, OrbusNeich focuses on medical products for vascular intervention, including interventional cardiology treatments. It has also been expanding into neuro-intervention and structural heart markets.

The company claims to provide the world’s first dual therapy stents, as well as coronary stents, specialty balloons, and microcatheters. It has operations in China, the US, and the Netherlands with a distributor network covering more than 60 countries. There are also direct sales teams operating out of Hong Kong, Singapore, Malaysia, Japan, China, Germany, Switzerland, Spain and France.

“OrbusNeich is a global cardiovascular interventional device company. For years, it thrives in competitive overseas markets among other multinational cardiovascular giants. This is a strength rarely seen in other China-based high-value cardiovascular interventional device market participants,” Yi Zhou, general manager of Red Earth, said.

In the same space, MicroPort CardioFlow Medtech, a spinoff from China’s MicroPort Medical, listed in Hong Kong earlier this year. The company is a manufacturer of artificial valves that are installed through minimally invasive processes. It targets valvular heart disease, where the valves become too narrow and hardened to open or close fully.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Save this article  
• Send to  

• Topics
• Greater China
• Healthcare
• Expansion
• China
• Shenzhen Capital Group
• manufacturing
• CCB International Asset Management
• CICC
• China Merchants Capital